COTA, Inc., a healthcare technology company that uses real-world data (RWD) to bring clarity to cancer care, is pleased to announce a number of initiatives that are bringing enhanced understanding of COVID-19 in near real-time. Leveraging its past knowledge of real-world evidence applications and learnings, COTA has joined the COVID-19 Evidence Accelerator program, a joint initiative of Friends of Cancer Research (Friends) and the Reagan-Udall Foundation for the Food and Drug Administration. Through this initiative, COTA is delivering findings from its observational, real-world studies using data from over 3,000 patients hospitalized with COVID-19 within the Hackensack Meridian Health network.